Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

* ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibod...

2023-05-18 11:53 2864

Antengene Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031

- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody...

2023-05-18 02:47 2534

Antengene Announces NDA Submission for XPOVIO® in Indonesia

SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-05-17 08:30 2605

Antengene to Release Latest Results from the TORCH-2 Trial of mTORC1/2 Inhibitor ATG-008 in Poster Discussion at 2023 ASCO

SHANGHAI and HONG KONG, April 27, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2023-04-27 08:30 2640

Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting

* Five posters showcased progress with multiple preclinical and clinical programs, includingATG-0...

2023-04-17 20:22 1993

Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia

* Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugat...

2023-03-29 08:30 2144

Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation

SHANGHAI and HONG KONG, March 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2023-03-28 21:40 2189

Antengene Announces Five Upcoming Presentations at the 2023 American Association for Cancer Research Annual Meeting

– Five posters will showcase progress with multiple preclinical and clinical programs, including t...

2023-03-20 15:20 1747

Antengene Announces IND Approval for the Phase I CLINCH Trial of ATG-022 (Claudin 18.2 ADC) for the Treatment of Advanced or Metastatic Solid Tumors in China

- Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate...

2023-03-14 12:29 2301

Antengene to Present at the 41st Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 3, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2023-01-03 14:10 1306

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab)

- ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's ant...

2022-12-27 08:30 2906

Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

SHANGHAI and HONG KONG, Dec. 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...

2022-12-23 08:30 2808

Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022 (Claudin 18.2 ADC) in Patients with Advanced or Metastatic Solid Tumors

* Discovered in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate targeting th...

2022-12-09 08:30 2484

Antengene Appoints Amily Zhang as its Chief Medical Officer

SHANGHAI and HONG KONG, Dec. 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-12-08 08:30 2642

Antengene Appoints Amily Zhang as its Chief Medical Officer

Antengene Highlights Encouraging ATG-008 Efficacy Results From TORCH-2 Study in Combination with PD-1 Antibody in Relapsed/Metastatic Cervical Cancer

* An objective response rate (ORR) of 52.4% was observed in relapsed or metastatic cervical cance...

2022-11-15 16:51 1546

Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting

- Oral presentation highlights preclinical data with ATG-031, an in-house discovered anti-CD24 mo...

2022-11-11 08:30 2381

Preliminary Results from Two Clinical Studies of Selinexor to be Presented at 2022 ASH Annual Meeting

- Poster with updated Phase Ib TOUCH results suggest selinexor plus GemOx could provide a therapeut...

2022-11-07 14:38 1333

Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China

- ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved t...

2022-11-02 20:07 2379

Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

* ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights...

2022-10-31 20:22 2476

Antengene to Host Research and Development Day on November 15th and 17th, 2022

* Virtual English Session: Tuesday, November 15 at 8:30 AM – 12:00 PM Eastern Time November 15 at ...

2022-10-27 11:07 2937